DURECT is actively developing new therapeutics based on its Epigenomic Regulator Program and proprietary drug delivery platforms.
DURECT is a biopharmaceutical company focused on the development of medicines that provide meaningful advances in patient health and wellbeing.
DURECT's Investor section provides comprehensive information to existing and potential stockholders, including up-to-date stock information, financial reports, investor events and more.
An investigational non-opioid, locally-acting analgesic being evaluated for its ability to provide 3 days of continuous pain relief after surgery.
LEARN MORE >